

JUBILANT PHARMA LIMITED
(Company Registration No. 200506887H)
(Incorporated in the Republic of Singapore)
160 Robinson Road, #17-01 SBF Center, Singapore 068914

January 4, 2017

Singapore Exchange Securities Trading Limited
11 North Buona Vista Drive #06-07
The Metropolis Tower 2
Singapore 138589


Dear Sirs,

We enclose a communication regarding signing of contracts for Radiopharma business.

This is for your kind information and records.

Thanking you,

Yours faithfully,
For Jubilant Pharma Limited

A handwritten signature in black ink, appearing to be 'Shanker Iyer', written over a horizontal line.

Shanker Iyer
Director

Encl.: as above



Jubilant Life Sciences Ltd.

1A, Sector 16A, Noida – 201301, India

Tel.: +91 120 4361000

www.jubl.com

Jubilant announces signing of long term contracts in Radiopharma business

Noida (UP), India, Wednesday, January 4, 2017

Jubilant Life Sciences Ltd, an integrated global Pharmaceuticals and Life Sciences Company, has announced that its wholly own subsidiary Jubilant Pharma Limited, through one of its units Jubilant DraxImage Inc. Montreal Canada (JDI), has signed long term contracts with distribution networks in the US for supply of products used for diagnostic and therapeutic procedures for thyroid, myocardial perfusion, lung, kidney and bone scans to be supplied by JDI over a period of 39 months effective from January 2017.

Commenting on the occasion, **Mr. Shyam S. Bhartia, Chairman and Mr. Hari S. Bhartia, Co-Chairman and Managing Director, Jubilant Life Sciences Limited** said: “We are delighted to announce signing of long term contracts by our Jubilant Draximage business where we are the leader in some of the key products in the US market. These contracts provide visibility on our future revenues with the differentiated and niche products in our Specialty Pharma business and will strengthen the company for its growth, going forward.”

About Jubilant Life Sciences Limited

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions. The Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non-sterile products through 6 USFDA approved manufacturing facilities in India, USA and Canada. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through 5 manufacturing facilities in India. The Drug Discovery Solutions segment, provides proprietary in-house innovation & collaborative research and partnership for out-licensing through 3 world class research centres in India and USA. Jubilant Life Sciences Limited has a team of around 6,600 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com.



For more information, please contact:

For Investors

Ravi Agrawal / Anupam Jain
Jubilant Life Sciences Limited
Ph: +91-120 436 1002 / 1021
E-mail: ravi_agrawal@jubl.com
anupam_jain@jubl.com

Siddharth Rangnekar / Karl Kolah
Citigate Dewe Rogerson
Ph: +91 22 6645 1209 / 1220
E-mail: siddharth@cdr-india.com
karl@cdr-india.com

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.